Back to results
US 2017/0304316 A1Published application
Ophthalmic Solution
AssigneeSentiss Pharma Private Limited
InventorsMandar V. Shah, Deepak Bahri
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeSentiss Pharma Private Limited
InventorsMandar V. Shah, Deepak Bahri
Estimating the term…
Disclosed herein an ophthalmic formulation comprises carbonic anhydrase inhibitor(s) alone, in an aqueous solution or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents and a manufacturing process thereof. The present invention further relates to the composition(s) manufactured by the process described herein and methods for treating persons suffering from glaucoma or ocular hypertension. In particular, the persons are treated with carbonic anhydrase inhibitor(s) alone or a combination of two intraocular pressure (IOP) reducing and/or glaucoma treatment agents or a combination of three intraocular pressure (IOP) reducing and/or glaucoma treatment agents to control their intraocular pressure (IOP). Further disclosed herein the formulations as manufactured relate to a highly solubilized form of poorly insoluble drugs/active ingredient(s) to improve its bio-availability and manufacturability.
An aqueous sterile, ophthalmic pharmaceutical formulation for lowering intraocular pressure in a patient suffering from elevated intraocular pressure comprising a carbonic anhydrase inhibitor or its pharmaceutically acceptable salt as an active agent and a polymer and a second or, third therapeutically active agent optionally along with pharmaceutically acceptable excipients and/or mixtures thereof, wherein the formulation is in solution form.
4-6. (canceled)
10-11. (canceled)
15-17. (canceled)
20-22. (canceled)
26-27. (canceled)
31-32. (canceled)
Dependencies are inferred from the claim text.